 CAMBRIDGE, Mass.--BUSINESS WIRE--Sage Therapeutics Nasdaq: SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the launch of SageCitizen a corporate social impact effort that activates and amplifies Sages long-term commitment to People, Patients, Planet and Community. At the core of our work at Sage is our mission to transform the lives of people with brain 